logotype

iPAAC

iPAAC - Innovative Partnership for Action Against Cancer

The Innovative Partnership for Action Against Cancer (iPAAC) Joint Action brings together 24 partners across Europe whose main objectives are to build upon deliverables of the CANCON Joint Action and to implement innovative approaches to cancer control. A Roadmap on Implementation and Sustainability of Cancer Control Actions will be the main deliverable of this Joint Action.

 

The general objective of the iPAAC Joint Action (JA) is to develop innovative approaches to advances in cancer control. The innovation that will be covered within the JA consists of further development of cancer prevention, comprehensive approaches to the use of genomics in cancer control, cancer information and registries, improvements and challenges in cancer care, mapping of innovative cancer treatments and governance of integrated cancer control, including a new analysis of National Cancer Control Plans. The key focus of the Joint Action will be on implementation, as reflected in the key deliverable, i.e. the Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support member states in the implementation of iPAAC and CANCON recommendations.

 

Background:

Cancer continues to present one of the key public health challenges in the European Union. Over the last 8 years, we have seen an intensification of the activities at the level of the European Union in order to tackle cancer from different aspects. Still, a number of important outstanding issues in cancer control remain unaddressed. The Innovative Partnership for Action Against Cancer (iPAAC), which has been selected for funding under the Third Health Programme 2014–2020, aims to build upon the outcomes of previous EPAAC and CANCON Joint Actions.

The iPAAC Joint Action has officially started on 1 April 2018 and it will last for three years. It includes 40 partners from 24 European countries and will be coordinated by the National Institute of Public Health Slovenia (NIJZ). More information about the iPAAC Joint Action can be obtained by visiting the official website (www.ipaac.eu) or by contacting the coordination team (This email address is being protected from spambots. You need JavaScript enabled to view it.).

 

Project Partners:

   

 

Work Packages:

 

 Work Package Description:

WP 1: Coordination
WP-Leader: National Institute of Public Health Slovenia (Tina Lipuscek)

The main objective of the Coordination Work Package is to ensure that the Joint Action fulfils the necessary
administrative and budgetary
requirements, as well as fulfils the general and specific objectives set out in this proposal.

WP 2: Dissemination
WP-Leader: Institute of Health Information and Statistics, Czech Republic (Ladislav Dušek)

WP2 main objective is to set up multiple channels and strategies disseminating key messages and recommendations of JA to main targets and audiences. The main effort of the WP2 will be focused on two principal targets which should be addressed via specific channels and tools and which can absorb relatively different content of messages:

- health care professionals, stakeholders, political authorities
- patients, their relatives, general public

WP 3: Evaluation of the project
WP-Leader:Croatian Institute of Public Health (Mario Šekerija)

Work package 3 will focus on evaluation of the iPAAC Joint Action. The goal of the evaluation is firstly to evaluate the design of the project, to continuously perform a rigorous analysis of the goals, objectives and activities in each of the work package, and to determine whether the project as a whole has produced planned results, delivered expected benefits, and made desired change.

WP 4: Integration in national policies and sustainability
WP-Leader:Scientific Institute of Public Health, Belgium (Regin Kiasuwa Mbengi)

This work package covers two key aspects of efficient policy making: implementation and sustainability. Considering that a JA is a relatively short project (3Y), implementation can realistically only be achieved starting from a common ground of understanding on actions to be taken for a particular issue. We propose to take the ‘European Guide on quality improvement of cancer control”1 developed in the former Joint Action CanCon as the basis and develop a so-called Roadmap on implementing the recommendations set out therein. (Alternative title: “Roadmap towards implementing the policy recommendations of the EU Guide on quality improvement in cancer control”)

WP 5: Cancer Prevention
WP-Leader: Cancer Society of Finland (Satu Lipponen)

  • Update, build awareness and strengthen implementation of the European Code Against Cancer (ECAC) in Member States
  • Plan a sustainable monitoring system with a follow-up structure for ECAC
  • Target vulnerable populations to reduce inequalities and foster
    health promotion (building upon the CanCon policy papers and the Guide)
  • Reinforce cancer prevention via population-based screening programmes, further developing the principles of the 2003 EU recommendations on screening
  • Identify data collaboration partners and to describe the process leading to better implementation of screening.
  • Strengthen screening practices with quality criteria and to remove obstacles of early detection of cancer
 

WP 6: Genomics in cancer Control and care
WP-Leader: Scientific Institute of Public Health, Belgium (Marc Van den Bulcke)

  • As it is imperative that the population is actively supporting this paradigm shift in healthcare, a societal debate on ethical, legal and privacy issues on the use of genome information in healthcare is needed
  • While considered as a promising future development, stratified screening by genetic testing of high-risk cancer patients requires evidence-based decisions and strict regulation of any enrolled initiative
  • Implementing precision genomics in medical care may have profound impact on health professionals work experience, on data registration management systems and national healthcare budgets if not introduced in a carefully planned stepwise approach
  • It is necessary to jointly develop a strategy how to deal with ‘Direct to Consumer’ testing within the healthcare system
  • Education and training on genomics of health professionals, policy makers and the citizens is a key element to full success of this new paradigm in healthcare      

WP 7: Cancer information and registries
WP-Leader: Italian National Institute of Health, Italy (Roberta De Angelis)

WP7 general objective is to enhance population-based cancer information systems to better support evidence-based comprehensive cancer care, with a focus on patterns of care, costs of care and survivorship. IPAAC JA should foster this enhancement, both at local and national level, and ensure in parallel a high level of standardisation and comparability in the procedures to collect and process data among the participating MS at EU level.

WP 8: Challenges in cancer care
WP-Leader: Catalonia Institute of Oncology, Spain (Josep M.Borras Andres)

The aim of the work package is to define strategies to improve the quality of cancer care by optimising the use of healthcare resources and promoting realistic and evidence-based responses to existing needs. While cancer care has evolved, showing better organisation and specificity with regards to treating different cancer diseases, cross-cutting and disease-based challenges remain

WP 9: Innovative cancer therapies
WP-Leader: French National Cancer Institute (Muriel Dahan)

This WP aims at mapping all the existing guidelines on innovative treatments on cancer and creates a database accessible for professionals. It is proposed to focus the WP on immunotherapies which currently represent the most innovative cancer treatments options and reflect the many challenges faced regarding the proper use of cancer drugs (clinical use & compliance with existing clinical guidelines), the numerous clinical developments (many clinical trials relate to immunotherapy and concern many therapeutic indications in oncology), the identification of responders (biomarkers are currently assessed to identify the best responders to immunotherapy), the anticipation of incoming new therapies & rising costs using systems like Horizon Scanning, the drug assessment based on real-life monitoring.

WP 10: Governance in integrated and comprehensive cancer care
WP-Leader:Federal Ministry of Health, Germany (Simone Wesselmann)

Governance means different things on different levels and has different implications depending on the perspective. That is why it is a key concept to be addressed in a systematic way. A conceptual model is needed in order to describe and better understand governance in each country. At this purpose a valid reference model, as also suggested by the CANCON-Guide, is the stewardship model proposed by WHO. Governance here is to be understood in this conceptual framework. The goal of this work package is to further develop practical instruments ensuring a standardized integrated and comprehensive oncological care in all European member states which is tumour-specific and delivers all-encompassing high-quality care to all patients. The goal of this work package is to further develop practical instruments ensuring a standardized integrated and comprehensive oncological care in all European member states which is tumour-specific and delivers all-encompassing high-quality care to all patients.